The U.S. Food and Drug Administration recently announced two developments that, taken together, mark a meaningful shift in how the agency is operationalizing artificial intelligence (AI) at the FDA: an expansion of its internal AI capabilities and the completion of a long‑running effort to consolidate FDA data systems into a unified platform. This announcement was framed as infrastructure—not as a new policy or regulatory position. That distinction matters. From FDA AI pilo

“Integration” has become a catch-all term in conversations about compliant AI deployments in pharma, secure clinical documentation platforms, and audit-ready AI workflows. Too often, it is used to describe surface-level connectivity—systems exchanging files or triggering downstream actions—rather than true workflow integration. In regulated writing environments, this distinction matters. Identity, versioning, traceability, and review context are not conveniences; they are le